Pharmaceutical Aspects of Intranasal Delivery of Vaccines Using Particulate Systems
- 1 March 2009
- journal article
- review article
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 98 (3) , 812-843
- https://doi.org/10.1002/jps.21493
Abstract
No abstract availableKeywords
This publication has 232 references indexed in Scilit:
- Uptake of microparticles into the epithelium of human nasopharyngeal lymphoid tissueMedical Molecular Morphology, 2006
- Nasal immunization studies using liposomes loaded with tetanus toxoid and CpG-ODNEuropean Journal of Pharmaceutics and Biopharmaceutics, 2006
- Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA deliveryAdvanced Drug Delivery Reviews, 2005
- Strong local and systemic protective immunity induced in the ferret model by an intranasal virosome-formulated influenza subunit vaccineVaccine, 2004
- Potent, long lasting systemic antibody levels and mixed Th1/Th2 immune response after nasal immunization with malaria antigen loaded PLGA microparticlesVaccine, 2004
- Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in miceEuropean Journal of Pharmaceutics and Biopharmaceutics, 2003
- Regional specialization in the mucosal immune system: what happens in the microcompartments?Immunology Today, 1999
- Immunology of the tonsilsImmunology Today, 1998
- Current options for vaccine delivery systems by mucosal routesJournal of Controlled Release, 1997
- Liposomes and ISCOMS as vaccine formulationsBiochimica et Biophysica Acta (BBA) - Reviews on Biomembranes, 1995